Article Details

Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102

Retrieved on: 2021-08-10 03:56:15

Tags for this article:

Click the tags to see associated articles and topics

Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102. View article details on hiswai:

Excerpt

... including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies ...

Article found on: www.bakersfield.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up